Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.
The Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development market research report provides an in-depth analysis of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
Mechanisms of Action of Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market
The mechanism of action of the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is Proto Oncogene Tyrosine Protein Kinase Src Inhibitor.
Routes of Administration in Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market
The routes of administration in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are oral, intravenous, and inhalational.
Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market
The molecule type in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is small molecule.
Key Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market Companies
Some of the key companies in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are Turning Point Therapeutics Inc, AbbVie Inc, AstraZeneca Plc, Avalyn Pharma Inc, Boehringer Ingelheim International GmbH, Chengdu Fanxi Biopharma Co Ltd, Fratagene Therapeutics Srl, KeifeRx LLC, Lead Discovery Center GmbH, and Nanocopoeia LLC.
Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by companies
To know more about key companies, download a free report sample
Market report overview
Mechanism of Action | Proto Oncogene Tyrosine Protein Kinase Src Inhibitor |
Routes of Administration | Oral, Intravenous, and Inhalational |
Molecule Type | Small Molecule |
Key Companies | AbbVie Inc, AstraZeneca Plc, Avalyn Pharma Inc, Boehringer Ingelheim International GmbH, Chengdu Fanxi Biopharma Co Ltd, Fratagene Therapeutics Srl, KeifeRx LLC, Lead Discovery Center GmbH, Nanocopoeia LLC, and Prous Institute for Biomedical Research SA |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).
- Reviews of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) therapeutics and enlists all their major and minor projects.
- Assessment of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Chengdu Fanxi Biopharma Co Ltd
Fratagene Therapeutics Srl
KeifeRx LLC
Lead Discovery Center GmbH
Nanocopoeia LLC
Prous Institute for Biomedical Research SA
Taiwan Liposome Co Ltd
Turning Point Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the mechanisms of action of the Proto Oncogene Tyrosine Protein Kinase Src pipeline market?
The mechanism of action of the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is Proto Oncogene Tyrosine Protein Kinase Src Inhibitor.
-
What are the routes of administration in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market?
The routes of administration in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are oral, intravenous, and inhalational.
-
What are the molecule types in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market?
The molecule type in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is small molecule.
-
Which are the key companies in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market?
Some of the key companies in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are AbbVie Inc, AstraZeneca Plc, Avalyn Pharma Inc, Boehringer Ingelheim International GmbH, Chengdu Fanxi Biopharma Co Ltd, Fratagene Therapeutics Srl, KeifeRx LLC, Lead Discovery Center GmbH, Nanocopoeia LLC, and Prous Institute for Biomedical Research SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.